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A b s t r a c t
Arterial hypertension is a prevalent disease with great harming potential. After the age of 55 years the remaining lifetime risk 
of hypertension amounts to 90%. Despite the constant advances some important issues such as the cut-off blood pressure for 
the initiation of antihypertensive therapy or the therapeutic goal are debated.
In this review, we present — based on the available literature — the current concepts concerning the pathophysiology, epi-
demiology and antihypertensive therapy in patients aged 65 years or older.
The pathophysiology of hypertension in older patients in principle rests on stiffening of large conduit arteries, which leads 
to greater systolic and lower diastolic blood pressure. This in most older patients results in isolated systolic hypertension. 
Additionally most of these patients have low-renin hypertension. Data from large-scale clinical trials indicate that therapy of 
such individuals with thiazide-like diuretics and long-acting dihydropiridine calcium channel blockers as first-line medications 
reduces risk of complications. Based on results of recently published trials, meta-analyses, and prospective observations, the 
optimal on-treatment blood pressure values for most older hypertensive patients should be set within the 130–139 mmHg 
range. At present, lower values of standard office blood pressure in this group of patients have not been shown to be associ-
ated with additional benefits, and may be associated with a greater risk of adverse events. 
In conclusion, we recommend that for most patients aged 65 years or more, standard office systolic blood pressure should 
be cautiously reduced to within 140 and 130 mmHg, preferably with a thiazide-like diuretic, long acting dihydropiridine 
calcium channel blocker or their combination. 
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INTRODUCTION
Upon reaching the age of 55–60 years, the remaining lifetime 
risk of becoming hypertensive amounts to 90% [1, 2]. Arterial 
hypertension is considered to be one of the leading causes of 
mortality of older adults, mostly by increasing the risk of such 
cardiovascular (CV) complications as myocardial infarction, 
stroke, heart failure or dissection of aortic aneurysms [3–10].
Primary hypertension in older adults is associated with 
different pathophysiologic background than primary hyperten-
sion seen in younger adults. This in large part is related to the 
ageing process of the CV system and kidneys. The repetitive 
haemodynamic force exerted during each heart cycle by 
the contraction of the left ventricle leads to thickening and 
stiffening of the myocardium, due to accumulation of lipofus-
cine [11]. The repetitive distensions and recoils of the aorta, 
which securing the non-zero, appropriate level of diastolic 
blood pressure (DBP), lead to remodelling of the aorta [12]. 
In this process, elastine fibres are becoming fragmented, and 
the amount of collagen increases, along with a change of the 
prevailing type of collagen [13]. Likewise the cellular compo-
nent of the aortic media changes, with increase in fibrocytes 
[14], that results in progressive thickening and stiffening of the 
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aorta [12–14]. This alteration has three effects of paramount 
importance to the pathophysiology of arterial hypertension 
in older patients.
First, the reduced compliance leads to less buffering of 
systolic pressure, which in turn causes higher values of systolic 
blood pressure (SBP). 
Second, this means that less energy is stored and subse-
quently given back during diastolic elastic recoil of the aorta 
to the blood, resulting in lower DBP. 
Third, the pressure pulse wave travels faster in stiffer 
aortic wall, which results in faster return of reflected wave 
which additionally augments systolic and lowers diastolic 
pressure [15, 16].
Another important issue in relation to ageing is gradual 
loss of renal function. Apart from steady decrease of glo-
merular filtration rate, at a rate of approximately 1% per year 
after the age of 35 years, the ageing kidney loses its ability to 
maintain adequate baseline renin production. The baseline 
plasma renin activity (PRA) may thus be decreased by 30% to 
50%. In addition, the secretion of renin in response to typical 
stimuli such as assumption of supine position, low sodium diet 
or volume depletion (as in bleeding) is also blunted [17, 18]. 
Earlier research by Laragh et al. [19, 20] and some more re-
cent studies and trials [21, 22] suggested that antihypertensive 
therapy in the older patients might be guided by PRA [23, 24]. 
The fact that in the older patients hypertension is associated 
with low PRA may have important therapeutic consequences, 
in that the long-acting calcium channel blockers (CCB) and 
diuretics may be more efficacious than medications acting 
via blockade of the renin–angiotensin–aldosterone system. 
BLOOD PRESSURE LEVEL AND  
CARDIOVASCULAR RISK IN OLDER PATIENTS
The concept of harm associated with increasing level of 
blood pressure in older subjects was evolving over the past 
90 years. Whereas still in the 1930s it was believed that 
higher values of especially SBP in older people were essential 
for the preservation of good health [2, 25] (hence the term 
‘essential hypertension’ currently usually replaced by that of 
primary hypertension). Early results from the Framingham 
Heart Study indicated that in older subjects SBP rather than 
DBP conferred the bulk of the risk associated with hyperten-
sion [26]. This finding was independently confirmed by the 
MRFIT study [27, 28]. On the other hand, a number of clinical 
trials performed in the 1980s concentrated on DBP alone, 
to the point that some of them did not even report systolic 
pressure values. The culmination of this concept was the 
seminal meta-analysis in 1990 which established the relation 
between level of diastolic pressure and CV risk, supported by 
observations that upon lowering of diastolic pressure, CV risk 
is decreased [29, 30]. However, it was not until 10 years later 
that a similar meta-analysis, performed on data of individual 
patients at or above the age of 60 years with systolic pressure 
exceeding 159 mmHg, demonstrated that greater systolic 
pressure is associated with increasing risk of CV complications, 
per each 10 mmHg greater SBP there was 20%–30% higher risk 
of CV events as well as CV and all-cause mortality [6]. After 
adjustment for systolic pressure, lower diastolic pressure was 
associated with greater risk of death, underlying the impor-
tance of pulse pressure as an independent risk factor in older 
patients with isolated systolic hypertension. These results were 
in line with earlier research which demonstrated that indices 
of arterial stiffening, primarily pulse pressure and pulse wave 
velocity, are incrementally associated with elevated risk of CV 
events in patients with a broad spectrum of clinical settings 
[31], including older patients with isolated systolic hyperten-
sion, end stage kidney disease, and diabetes mellitus [31–36]. 
THE EVIDENCE TO SUPPORT THERAPY
Over the past quarter of century, four major placebo-con-
trolled trials of antihypertensive therapy in older patients 
with isolated systolic hypertension have been published. 
The Systolic Hypertension in the Elderly Program (SHEP), 
published in 1991, included 4736 patients aged 60 years or 
more (57% women) who were randomly assigned either to 
active regimen based on thiazide-like diuretic chlorthalidone 
with possible addition of atenolol, and reserpine, or matching 
placebos. After the average follow-up of 4.5 years actively 
treated patients as compared to the placebo group had 36% 
lower risk of all stroke, 27% reduction of the risk of coronary 
artery disease, and 32% reduction of the risk of combined CV 
events (all p < 0.01) [37, 38]. The results of this trial have to 
be analysed cautiously as only 1% of the original screening 
population was finally enrolled. In the Systolic Hypertension 
in Europe (Syst-Eur) trial, 4695 patients aged 60 years or more 
(66% women) were randomised to receive either nitrendipine 
(a dihydropiridine calcium channel blocker [CCB-DHP]) based 
therapy with possible sequential addition of enalapril, and 
hydrochlorothiazide, or matching placebos. After a median 
follow-up of two years the trial was stopped prematurely 
because actively treated patients had 42% lower risk of all 
stroke, 26% reduction of the risk of cardiac events, and 31% 
reduction of the risk of CV events combined (all p ≤ 0.03) [39]. 
The Systolic Hypertension in China (Syst-China) trial replicated 
the results of Syst-Eur in the Chinese population, showing, 
after two years of follow-up on average, 38% reduction of all 
stroke, 39% reduction of CV mortality, and 39% reduction 
of the risk of all-cause death (all p ≤ 0.03) [40]. The results 
of Syst-China were at times disregarded due to the fact that 
instead of randomisation the protocol provided for alternate 
allocation of patients into the respective arms. However, as 
can be judged by the comparison of baseline characteristics 
between the two groups, such study design did not result in 
a systematic bias [40, 41]. Finally, the Hypertension in the Very 
Elderly Trial (HYVET) included 3845 patients (61% women) at 
or above the age of 80 years and randomly assigned to active 
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treatment based on thiazide-like diuretic indapamide with 
possible addition of perindopril or matching placebos [42]. 
After follow-up of 2.1 years the actively treated patients had 
30% lower risk of stroke (p = 0.06), 23% lower risk of CV 
death (p = 0.06), and 21% lower risk of death of all causes 
(p = 0.02). Moreover, the actively treated patients had 64% 
lower risk of heart failure (p < 0.001) [42]. However, this 
benefit may be attributed to a confounding factor, namely 
the medications used to treat hypertension in this trial came 
from drug classes constituting the cornerstone of medical 
therapy of heart failure. The interpretation of the HYVET trial 
is challenging because the population enrolled was extremely 
healthy and only about one third of the patients in this group 
of very old hypertensives had isolated systolic hypertension. 
Both facts preclude the application of the study results to the 
overall population of hypertensives above the age of 80 years 
[43, 44].
A number of active control studies were performed in 
a population of older patients with hypertension. Of these, 
the Losartan Intervention For Endpoint reduction in hyper-
tension (LIFE-ISH, substudy in patients with isolated systolic 
hypertension and left ventricular hypertrophy) trial showed 
that therapy based on losartan with possible addition of hy-
drochlorothiazide, as compared to therapy based on atenolol 
with possible addition of hydrochlorothiazide, reduced the 
composite endpoint of stroke, myocardial infarction and CV 
death by 25% (p = 0.06) [45]. Of particular importance is 
the fact that the trial did not demonstrate blood pressure dif-
ference between the two therapeutic arms [45]. The Second 
Australian National Blood Pressure Program (ANBP2) dem-
onstrated 11% (p = 0.05) reduction of the relative risk of all 
CV events or death from any cause with therapy based on 
enalapril as compared to diuretic-based regimen. However, 
this marginal effect was driven by the outcome in men en-
rolled to the study population. No effect was seen in women 
[46]. Like in the LIFE-ISH trial [45], the ANBP2 did not show 
the between-group difference in blood pressure [46]. The 
SCOPE (The Study on Cognition and Prognosis in the Elderly; 
candesartan/hydrochlotothiazide + amiloride vs. placebos) 
[47], SHELL (The Systolic Hypertension in the Elderly study; 
lacidipine vs. chlorthalidone) [48], and INSIGHT-ISH (The 
International Nifedipine GITS Study: Intervention as a Goal 
in Hypertension Treatment, subanalysis in isolated systolic hy-
pertension; nifedipine GITS/atenolol/enalapril vs. hydrochlo-
rothiazide/atenonol/enalapril) [49] did not produce evidence 
in favour of the use of any particular medications. Overall, 
current evidence supports use of diuretics and long-acting 
CCB-DHP as the mainstay of antihypertensive therapy in 
older patients with isolated systolic hypertension and no other 
compelling indications [50–54]. 
Of the diuretics the preferred group would include 
thiazide-like compounds, as hydrochlorothiazide has been 
shown to be of dubious value at lower doses and potentially 
fraught with unfavourable side effects at blood pressure lower-
ing doses equipotent to those of indapamide or chlorthalidone 
[55]. Furthermore, hydrochlorothiazide, which is a photosen-
sitiser, has been shown to increase the risk of nonmelanoma 
skin cancer. In a nationwide Danish study the cumulative 
dose of hydrochlorothiazide of more than 50,000 mg has 
been associated with 29% greater risk of basal cell carcinoma 
(p for trend < 0.001) and 398% greater risk of squamous cell 
carcinoma (p for trend < 0.001) [56].
Based on the results of the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT), where regimen based on combi-
nation of long-acting CCB-DHP amlodipine and angioten-
sin-converting enzyme inhibitor (ACEI) perindopril and was 
superior to combination of b-blocker atenolol and thiazide 
diuretic bendroflumethiazide [57], the use of the combination 
of ACEI and CCB-DHP has been advocated, including the 
older patients [57, 58]. Indeed the ASCOT results indicated 
that the benefit was present independent of whether the 
patients were younger than 60 years or older [57]. However, 
the use of atenolol as a comparator has been widely criticised 
[59–61], as the medication is believed to confer little or no 
benefit in hypertensive subjects [62, 63]. Moreover, in older 
subjects atenolol may even increase central blood pressure, 
as was demonstrated in the CAFE study [64]. 
Another issue is the use of alpha-adrenolytic medica-
tions such as doxazosin, which may be tempting especially 
in older male patients with hypertension and coexisting be-
nign prostatic hyperplasia. Since the publication of an initial 
report of the Antihypertensive and Lipid-Lowering Treatment 
to Prevent Heart Attack Trial (ALLHAT) [65, 66], doxazosin 
has been moved to the third or even fourth line of antihy-
pertensive regimens, especially in the elderly [54]. However, 
the closer scrutiny of the ALLHAT report reveals possibility of 
significant bias [65]. First, during the run-in period of the trial 
patients were to undergo a wash-out period, during which 
previous antihypertensive therapy was discontinued. Then, 
the patients were randomly assigned to one of four arms, 
including chlorthalidone and doxazosin. The doxazosin arm 
was discontinued prematurely because significantly more 
patients had episodes of heart failure and CV disease. How-
ever, neither the primary outcome of coronary heart disease, 
nor all-cause mortality differed between the doxazosine and 
chlorthalidone groups [65]. Of note, patients in the doxazosin 
arm during the entire trial had systolic pressure higher by 2 to 
3 mmHg than individuals assigned to chlorthalidone; the 
difference was likely to account for a 5% to 9% difference in 
outcome [6]. Clearly, doxazosin is neither first nor second line 
antihypertensive medication in the older patients, especially 
in monotherapy of patients with or at high risk of developing 
heart failure. Doxazosin must be used with caution and should 
best be avoided in patients with orthostatic hypotension. 
However, in patients in whom escalation of antihypertensive 
regimen is needed, especially those who would not tolerate 
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anti-aldosterone compounds, or in male subjects with co-
existing benign prostatic hyperplasia, doxazosin may still be 
useful, although to limit the risk of side effects the long-acting 
formulation should be preferred [54]. 
An all-important question of the cut-off for the definition 
of hypertension and the initiation of antihypertensive therapy 
has recently been refueled with the publication of the results 
of the SPRINT trial results and SPRINT-AGED subanalysis 
[67]. SPRINT was a randomised trial evaluating the intensive 
(< 120 mmHg) or standard (135–139 mmHg) goal of antihy-
pertensive therapy. The study, which was carried according 
to the PROBE (prospective, randomised, open-label, blinded 
endpoint assessment) design [68], included hypertensive 
patients aged over 50 years with SBP values of between 
130 and 180 mmHg. The patients had to be free from diabetes 
mellitus but otherwise they had to be burdened by high CV 
risk profile [67]. The main report described the data on the 
initial cohort of 9361 patients. Overall, the trial demonstrated 
significant reduction of relative risk of sustaining the primary 
composite endpoint of non-fatal acute coronary syndrome 
(including non-fatal myocardial infarction), non-fatal stroke, 
non-fatal exacerbation of heart failure and CV death, by 25% 
(p < 0.001) and all-cause death by 27% (p = 0.003) [67]. The 
subgroup analysis in older patients showed that the relative 
risk of composite primary endpoint as described above, was 
reduced by 34% (p = 0.001) and death of all causes by 33% 
(p = 0.009) [69]. In the entire study group, these benefits were 
achieved at the statistically significant cost of an increase in the 
risk of hypotension, acute renal failure, and hyponatraemia 
of the magnitude similar to that of the reported benefit [67, 
70]. In the subgroup of patients older than 75 years, there was 
a marginally non-significant trend for a greater relative risk of 
hypotension by 71% and syncope by 23% [69]. 
The interpretation of both reports of the SPRINT trial 
poses several problems. First, the blood pressures reported by 
the authors were not standard office measurements. Instead, 
blood pressures were measured with an automated oscyllo-
metric device with the patient left at his or her leisure without 
presence of a healthcare professional. A number of studies 
demonstrated that the unattended blood pressure measure-
ments may be associated with 9.0–15/6.0–8.0 mmHg lower 
SBP/DBP values as compared to standard office measurements 
[71–73]. This led Filipovský et al. [73] to the conclusion that 
the level of unattended blood pressure corresponding to office 
blood pressure of 140/90 mmHg should be 125/82 mmHg, 
systolic and diastolic pressure, respectively.
All of the recently performed large-scale clinical trials used 
measurement of blood pressure in an attended fashion. This 
drawback makes the comparisons of the outcome of these 
trials and the SPRINT feasible only when the adjustment for 
the difference in blood pressure using different methods is 
taken into consideration [74]. However, this is not where the 
interpretational problems of the SPRINT trial stop. In order to 
separate the groups on the basis of achieved blood pressure, 
the provision had been made in the protocol to the effect that 
a patient randomised to standard therapy with the average SBP 
of 130 mmHg or less during a single visit or with the average 
SBP of 135 mmHg or less during two consecutive visits should 
have his or her medications tapered down in order to maintain 
the SBP between 135 and 139 mmHg [67, 75]. According 
to data presented in the main report of the trial, at the initial 
visit alone, there were about 15,000 such persons [67]. The 
report on the participants aged 75 years or more does not cite 
the blood pressure strata, however some information may be 
extrapolated based on the similar behaviour of systolic pres-
sure in the standard treatment group in both the principal and 
the 75+ reports of the SPRINT trial [67, 69]. The subgroup 
analysis according to initial SBP in the entire study group dem-
onstrated that only in the patients from the lowest unattended 
SBP stratum (< 132 mmHg) a statistically significant reduction 
of the risk of endpoints was achieved. This finding may in part 
reflect the fact that this group included the bulk of patients 
who had their medications tapered down, and that patients 
from this group would have achieved adequate control of SBP 
if office values had been substituted for unattended measure-
ments. The closer scrutiny of the blood pressure graphs leads 
to the conclusion that in the strict blood pressure control group 
SBP averaged 129.1 mmHg at one month and further fell by 
2.5 mmHg by six months and by additional 0.2 mmHg by 
one year, when it averaged 126.4 mmHg. On the other hand, 
SBP in the standard treatment group at one month averaged 
131.3 mmHg and increased by the time of six-month visit by 
0.6 mmHg and by further 0.7 mmHg by one year into the 
trial, averaging 132.6 mmHg (visual inspection of Figure 2 
from reference [67]). Based on the previous research one can 
assume that the thus produced 6.2 mmHg between-group 
difference in SBP could have been translated into 16% greater 
relative risk of all CV events in the standard treatment group 
compared with the strict blood pressure control group [6]. 
When corrected according to data published by Filipovský et 
al. [73], these one year unattended SBP readings would be 
141.4 mmHg in the strict control group and 147.6 mmHg in 
the standard control group. This observation is somewhat in 
line with the largely negative results of the Japanese Trial to 
Assess Optimal Systolic Blood Pressure in Elderly Hypertensive 
patients (JATOS), in which the reduction of SBP on average to 
below 140 mmHg did not offer more benefit in older Japanese 
patients as compared to less strict blood pressure control to 
below 160 mmHg [76]. 
After the publication of the SPRINT results, a number of 
meta-analyses, which included the summary data of this trial 
appeared. These meta-analyses advocated that SBP should 
be universally reduced to below 130 mmHg [77–79]. In 
these reports the sheer weight of the SPRINT group seemed 
to draw the results towards lower blood pressure goals to be 
achieved with antihypertensive therapy. However, due to the 
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aforementioned problems concerning interpretation of the 
SPRINT trial, despite the sincerity of the effort on the part 
of the authors of the cited meta-analyses and the investiga-
tors of the SPRINT trial, the conclusions to the effect that all 
our hypertensive patients, irrespective of age, should have 
their office SBPs reduced to below 130 mmHg seem rather 
far-fetched. In fact, if data by Lund-Johansen et al. [71], Man-
cia et al. [72] and recently Filipovský et al. [73] are correct, 
the SPRINT was a trial assessing the standard control of blood 
pressure versus no control. 
The possible practical answer to the question of the 
evidence supporting the particular level of SBP, when meas-
ured by a physician or a nurse in an office setting, may be 
supported by the two post-hoc analyses of the INternational 
VErapamil SR-Trandolapril STudy (INVEST) [80, 81]. An analy-
sis published by Denardo et al. [80] demonstrated that the 
achieved, on-treatment, SBP at which risk is lowest differs ac-
cording to patients’ age. Whereas, SBP in younger individuals 
can be safely decreased to below 140 mmHg and no harm 
is observed at as low values as 120–130 mmHg, in patients 
older than 70 years of age the lowest risk is noted with the SBP 
around 140 mmHg and when the achieved values decrease 
to below 135–140 mmHg, the risk starts increasing [80]. Of 
note, the U-shaped relation between achieved blood pressure 
and CV risk was present for both SBP and DBP [80]. Elgendy 
et al. [81] brought these results a step further. In a report 
published in 2016 they demonstrated that after maximum 
of 11 years of extended follow-up for fatal events, the lowest 
risk for older patients was associated with SBP of between 
130 and 140 mmHg, with slightly less favourable results for 
SBP below 130 mmHg and between 140 and 150 mmHg, 
and much worse outcomes in patients with SBP exceeding 
150 mmHg [70, 81]. However, the analysis by Elgendy et al. 
[81] is not free of potential flaws, as the blood pressure values 
on which they base their estimates extended only to 2.7 years 
of average follow-up. 
A recent meta-analysis lent support to lowering of SBP in 
older hypertensive patients to values below 140 mmHg [82]. 
The authors demonstrated that such therapy reduces major 
adverse CV events by 29% (p < 0.001), all-cause mortality by 
33% (p = 0.04), and heart failure by 37% (p = 0.04), however 
this may come at a cost of polypharmacy, and increased risk 
of such complications as acute kidney injury, hypotension, 
and syncope [82].
Further evidence came with the publication of data from 
the Heart Outcomes Prevention Evaluation (HOPE)-3 trial, 
which indicated that lowering of SBP to less than 130 mmHg 
with active antihypertensive therapy in intermediate risk 
subjects, with a mean age of 65.7 and no CV disease, with 
an exception for individuals with initial SBP values exceeding 
143.5 mmHg, did not confer CV benefit [83, 84]. The benefit 
in these individuals was restricted to the use of rosuvastatin 
with a marginally greater benefit associated with co-adminis-
tration of candesartan and hydrochlorothiazide [84].
CONCLUSIONS
The initiation of antihypertensive therapy or its up-titration 
should be performed carefully in older patients. One should 
remember that the population of older patients include on 
one hand generally healthy, biologically younger and fitter 
individuals, and on the other hand, frail individuals with high 
degree of comorbidity and polypharmacy. Whereas the former 
can be approached in a manner in many respects similar to 
our approaches to younger patients, the latter needs to be 
addressed more specifically [44]. The importance of the ap-
proaches taking into consideration patient’s age is wide-rang-
ing. From the issues concerning compliance [85], through 
potential complications of therapy such as hyponatraemia, 
hypotension and falls, to a possible inadvertent increase in 
the risk of CV events in cases where achieved blood pressure 
would be inappropriately high or inappropriately low [70, 86].
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